Tempest Therapeutics FY2022 net loss $35.7M; cash $31.2M; TPST-1120 HCC data H1 2023

Tempest Therapeutics, Inc.

Cash and equivalents $31.2M as of Dec 31, 2022, down from $51.8M; runway to Q2 2024.
Net loss $35.7M vs $28.3M in 2021; R&D expenses $22.5M (+31% YoY).
TPST-1120 Phase 1 showed 30% ORR at highest doses in checkpoint-inhibitor non-responsive patients.
Randomized Phase 1b/2 study in first-line HCC fully enrolled; initial data expected H1 2023.
TPST-1495 Phase 1 dose escalation ongoing; initial data expected by mid-2023.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 1.0

Tempest Therapeutics, Inc. reported the year ended December 31, 2022 results: net income $35.7 million, EPS $3.09.

Period: the year ended December 31, 2022
Net income: $35.7 million
EPS: $3.09
Result: reported results

Exact text from the filing

Net loss and net loss per share for the year were $35.7 million and $3.09, respectively, compared to $28.3 million and $7.47, respectively, for the same period in 2021.

View on SEC.gov

49 earnings releases filed in the last 30 days. Browse all earnings releases →

Tempest Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-23-009236

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.